| |  Prostate cancer remains a global health challenge, ranking as the second most common malignancy among men. | |
|
| |  Prostate cancer is among the most common cancers in men and a leading cause of cancer-related deaths. With improved detection and therapies, survival rates have risen, but this progress comes with a new concern: the risk of secondary primary malignancies. | |
|
| |  Today, the American Cancer Society (ACS) released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. | |
|
| |  Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers present in urine, funded in part by the National Institutes of Health. | |
|
| |  A preclinical evaluation of a new 'dual-mode' tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and targeted guidance during surgery. | |
|
| |  Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States. | |
|
| |  Discover how transcription factors are revolutionizing drug discovery. | |
|
| |  Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, according to a new study led by UCL researchers. | |
|
| | Colorectal cancer is unique in having its own microbial 'fingerprint' – according to new research from the University of East Anglia. | |
|
| |  Prostate cancer is highly heterogeneous, ranging from slow-growing tumors to aggressive, life-threatening disease. | |
|
| |  Explore how Claudin 18.2-specific antibodies are transforming population screening by enabling more effective detection of cancer biomarkers. | |
